Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerome Barakos

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
JAMA Neurology|November 22, 2021
Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer DiseaseStephen Salloway, Spyros Chalkias, Frederik Barkhof, et al.
The Lancet. Neurology|March 2, 2010
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose studyJuha O Rinne, David J Brooks, Martin N Rossor, et al.
The Lancet. Neurology|February 7, 2012
Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysisReisa Sperling, Stephen Salloway, David J Brooks, et al.
CNS Drugs|December 1, 2025
Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer's Disease: Synthesis of Evidence from Observational and Interventional TrialsSusan Abushakra, P Murali Doraiswamy, John A Hey, et al.
Alzheimer'S & Dementia (New York, N. Y.)|March 6, 2023
Development, initial validation, and application of a visual read method for [<sup>18</sup>F]MK-6240 tau PETJoanna L Shuping, Dawn C Matthews, Katarzyna Adamczuk, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
JAMA Neurology|November 22, 2021
Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer DiseaseStephen Salloway, Spyros Chalkias, Frederik Barkhof, et al.
The Lancet. Neurology|March 2, 2010
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose studyJuha O Rinne, David J Brooks, Martin N Rossor, et al.
The Lancet. Neurology|February 7, 2012
Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysisReisa Sperling, Stephen Salloway, David J Brooks, et al.
CNS Drugs|December 1, 2025
Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer's Disease: Synthesis of Evidence from Observational and Interventional TrialsSusan Abushakra, P Murali Doraiswamy, John A Hey, et al.
Alzheimer'S & Dementia (New York, N. Y.)|March 6, 2023
Development, initial validation, and application of a visual read method for [<sup>18</sup>F]MK-6240 tau PETJoanna L Shuping, Dawn C Matthews, Katarzyna Adamczuk, et al.
Pageof 3